Navigation Links
Scientist clears hurdles for muscular dystrophy therapy
Date:10/29/2008

COLUMBIA, Mo. Approximately 250,000 people in the United States have some form of muscular dystrophy. Duchenne muscular dystrophy (DMD) is the most common type of the disease, predominantly affecting males. Boys with DMD will lose the ability to walk by their teens and typically die before the age of 30. For years, scientists have studied the use of gene therapy as a possible way to correct the muscle deterioration, but hurdles such as the need to treat all muscles in the body, including both skeletal muscle and heart muscle, have challenged researchers looking for an effective therapy until now.

In recent studies, published in Molecular Therapy and Human Gene Therapy, a team of University of Missouri researchers, led by Dongsheng Duan, associate professor of molecular microbiology and immunology, has found not only a delivery method that can reach every muscle of the body in a large animal model, but a therapy that will work on both skeletal muscle, the type found in arms and legs, and cardiac muscle, such as the heart.

"The difficult challenge with treating Duchenne muscular dystrophy, and other types of muscle-related diseases, is that the therapy must reach almost every muscle throughout the body," Duan said. "We have found that our new therapy, which uses a particular virus to deliver the gene therapy, reaches all of the muscles in large animals. This development raises the hope of whole body correction of Duchenne muscular dystrophy."

Patients with Duchnne muscular dystrophy have a gene mutation that disrupts the production of a protein known as dystrophin. Absence of this protein starts a chain reaction that eventually leads to muscle cell degeneration and death. Eventually, the damaged muscle tissue is replaced by fibrous, bony or fatty tissue and loses function. In the heart, this leads to severe heart disease and can place severe limitations on individuals afflicted with the disease.

In gene therapy, mutated genes are replaced with healthy genes. However, even with gene therapy, the healthy genes must reach every muscle in the body. Previously, scientists, including Duan's team, have experimented using viruses to deliver the healthy genes. However, these earlier studies were conducted in mice. Duan's team has now proven that this delivery system will reach every muscle in larger animals, such as dogs.

"Between 40 percent and 60 percent of the body weight is muscle, so it's vital that we find a way to deliver the therapy to every muscle in the body," Duan said. "Since dogs are 250 times the size of mice, but only nine times smaller than a human on average, we have taken a significant step in understanding if this therapy can work."

Duan's team has not stopped with just that discovery. In gene therapy, it is not feasible to fix every cell in the heart. Previously, scientists were uncertain whether partial correction could benefit patients. In an earlier study, Duan's research team demonstrated that heart tissue could be corrected enough to sustain a healthy life if only 50 percent of the tissue was affected by the therapy. Following the success with heart tissue, Duan's team has demonstrated for the first time that this result also is true with live heart muscle.

The Mizzou researchers delivered the therapy to the hearts of newborn mice with muscular dystrophy and found that gene therapy corrected many of the electrocardiogram abnormalities in these mice.

New tests have been developed to screen newborns with a high risk of muscular dystrophy. With few treatments available, the screening has not been widely accepted, but that may change if Duan's therapy proves to be effective.

"If you can treat an infant before they develop symptoms, you can treat the patient before they experience muscle loss," Duan said. "If you wait until symptoms start to appear, the muscle has already started to deteriorate. It's very difficult to treat when there is no muscle there."


'/>"/>

Contact: Christian Basi
BasiC@missouri.edu
573-882-4430
University of Missouri-Columbia
Source:Eurekalert

Related biology news :

1. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
2. UC Riverside scientist to explore how vegetation affects urban heat islands
3. European biodiversity and ecosystem scientists merge and gear up for long-term research
4. Scientists unveil mechanism for up and down in plants
5. Scientists identify cell changes leading to impaired artificial kidney function
6. Scientists achieve first tracking of salmon from headwaters in Rockies through Pacific to Alaska
7. NIAID scientists to speak on range of infectious disease topics at major scientific meeting
8. British scientists go cloud-hopping in the Pacific to improve climate predictions
9. Scientists map soils on an extinct American volcano
10. Scientists call for protected swimways for the endangered leatherback sea turtle
11. Scientists from Granada find a potential treatment to prevent diabetes and obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the addition ... offering. The report forecasts the global military biometrics market ... The report has been prepared based on an in-depth market ... and its growth prospects over the coming years. The report also includes ...
(Date:12/15/2016)... Mich. , Dec. 15, 2016  There is ... car doors or starting the engine. Continental will demonstrate ... Las Vegas . Through the combination ... Start and Entry) and biometric elements, the international technology ... of vehicle personalization and authentication. "The integration ...
(Date:12/12/2016)... CLEVELAND , Dec. 12, 2016  Researchers ... commercial possibilities for graphene by combining the material ... a highly sensitive pressure detector able to sense ... of a small spider.  The ... and can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... SAN DIEGO , Jan. 11, 2017 /PRNewswire/ ... first-in-class antibody product candidates focused on unmet medical ... Dominic Piscitelli as chief financial officer.  ... AnaptysBio,s finance strategy, as well as overseeing the ... "We are pleased to welcome Dominic to ...
(Date:1/11/2017)... MINNEAPOLIS , Jan. 11, 2017 ... Consortium (CBQC) today announced that it has partnered ... products for life science research and diagnostics. The ... a soluble form of receptor for advanced ... biomarker to support subject selection for clinical trials ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... enterprise-quality business communication technologies, with on premise functionality, from the cloud. MacDonald-Miller Facility ... partnership to leverage their existing Microsoft Office 365 E5 licensing to its maximum ...
(Date:1/10/2017)... ... January 10, 2017 , ... Clinical Supplies ... acquired B&C Group (“B&C”) based in Brussels, Belgium. CSM and B&C have had ... B&C and their management team into the CSM family. The addition of the ...
Breaking Biology Technology: